反応式
Cl[C:2]1[C:3]2[C:10]([CH3:11])=[CH:9][S:8][C:4]=2[N:5]=[CH:6][N:7]=1.[F:12][C:13]1[CH:14]=[C:15]([NH:20][C:21]([NH:23][C:24](=[O:33])[CH2:25][C:26]2[CH:31]=[CH:30][C:29]([F:32])=[CH:28][CH:27]=2)=[S:22])[CH:16]=[CH:17][C:18]=1[OH:19]>>[F:12][C:13]1[CH:14]=[C:15]([NH:20][C:21]([NH:23][C:24](=[O:33])[CH2:25][C:26]2[CH:27]=[CH:28][C:29]([F:32])=[CH:30][CH:31]=2)=[S:22])[CH:16]=[CH:17][C:18]=1[O:19][C:2]1[CH:3]2[C:10]([CH3:11])=[CH:9][S:8][CH:4]2[N:5]=[CH:6][N:7]=1参加物
3
実験手順
In a similar manner as described for the preparation of Example 10, the title compound was prepared from commercially available 4-chloro-5-methylthieno[2,3-d]pyrimidine and 1-(3-fluoro-4-hydroxyphenyl)-3-(2-(4-fluorophenyl)acetyl)thiourea (24 mg, 0.075 mmol, Compound A of Example 3). 1H NMR (CDCl3) δ 12.42 (s, 1H), 8.67 (s, 1H), 8.53 (s, 1H), 7.88 (dd, 1H, J=13.8, 2.2 Hz), 7.43 (s, 1H), 7.32 (m, 3 H), 7.09 (m, 3H), 3.72 (S, 2H), 2.67 (s, 3H); MS(ESI+) m/z 471 (M+H)+.
後処理
- customIn a similar manner as described for the preparation of Example 10
出典と根拠
- ORDレコード
- ord-e0fc7d4e8a6942258b12470d07200790
- 出典データセット
- uspto-grants-2007_02
- 特許番号
- US07173031B2
関連ノート
読み込み中…